达格列净对射血分数轻度降低或保留心衰患者KCCQ各组分的影响
该研究为DELIVER试验的事后探索性分析,纳入5795例射血分数>40%的症状性心衰患者,随机接受达格列净10mg每日一次或安慰剂。8个月时达格列净与几乎全部23个KCCQ组分改善相关,以呼吸困难所致活动受限、睡眠受限及下肢水肿频率改善最显著。
要点
- 达格列净改善KCCQ多个组分,尤以症状频率和体力活动受限领域获益最大。
- 下肢水肿频率差异3.2(95%CI 1.6-4.8),睡眠受限差异3.0(95%CI 1.6-4.4)。
- 达格列净组更多患者各组分改善、更少恶化。
核心结论
- 在射血分数轻度降低或保留的心衰患者中,达格列净与广泛的KCCQ个体组分改善相关,症状频率和体力活动受限领域获益最大。
研究设计与样本
- DELIVER试验的事后探索性分析,随机双盲安慰剂对照,20国353中心,2018年8月至2022年3月。
- 5795例有基线KCCQ数据的随机患者,平均年龄71.5岁,男性57.7%,女性42.3%。
- 纳入标准为症状性心衰、左室射血分数>40%、利钠肽升高及结构性心脏病证据。
- 干预为达格列净10mg每日一次或安慰剂,KCCQ在随机化及1、4、8个月时评估。
主要发现
- 8个月时达格列净与几乎全部23个KCCQ组分较安慰剂更大的改善相关。
- 改善最显著的是下肢水肿频率(差异3.2;95%CI 1.6-4.8;P<.001)。
- 睡眠受呼吸困难限制(差异3.0;95%CI 1.6-4.4;P<.001)和期望活动受呼吸困难限制(差异2.8;95%CI 1.3-4.3;P<.001)也显著改善。
- 纵向分析整合1、4、8个月数据观察到相似的治疗模式。
- 多数组分中达格列净组更高比例患者改善、更低比例恶化。
临床怎么用
- 可向射血分数轻度降低或保留的心衰患者说明达格列净可能改善呼吸困难相关活动受限、睡眠及下肢水肿。
- 特定症状和日常活动能力的改善可能更易被患者识别和沟通。
局限性
- 本研究为DELIVER试验的事后探索性分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Dapagliflozin has been shown to improve overall health status based on aggregate summary scores of the Kansas City Cardiomyopathy Questionnaire (KCCQ) in patients with heart failure (HF) with mildly reduced or preserved ejection fraction enrolled in the Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure (DELIVER) trial. A comprehensive understanding of the responsiveness of individual KCCQ items would allow clinicians to better inform patients on expected changes in daily living with treatment. OBJECTIVE: To examine the association of dapagliflozin treatment with changes in individual components of the KCCQ. DESIGN, SETTING, AND PARTICIPANTS: This is a post hoc exploratory analysis of DELIVER, a randomized double-blind placebo-controlled trial conducted at 353 centers in 20 countries from August 2018 to March 2022. KCCQ was administered at randomization and 1, 4, and 8 months. Scores of individual KCCQ components were scaled from 0 to 100. Eligibility criteria included symptomatic HF with left ventricular ejection fraction greater than 40%, elevated natriuretic peptide levels, and evidence of structural heart disease. Data were analyzed from November 2022 to February 2023. MAIN OUTCOMES AND MEASURES: Changes in the 23 individual KCCQ components at 8 months. INTERVENTIONS: Dapagliflozin, 10 mg, once daily or placebo. RESULTS: Baseline KCCQ data were available for 5795 of 6263 randomized patients (92.5%) (mean [SD] age, 71.5 [9.5] years; 3344 male [57.7%] and 2451 female [42.3%]). Dapagliflozin was associated with larger improvements in almost all KCCQ components at 8 months compared with placebo. The most significant improvements with dapagliflozin were observed in frequency of lower limb edema (difference, 3.2; 95% CI, 1.6-4.8; P < .001), sleep limitation by shortness of breath (difference, 3.0; 95% CI, 1.6-4.4; P < .001), and limitation in desired activities by shortness of breath (difference, 2.8; 95% CI, 1.3-4.3; P < .001). Similar treatment patterns were observed in longitudinal analyses integrating data from months 1, 4, and 8. Higher proportions of patients treated with dapagliflozin experienced improvements, and fewer had deteriorations across most individual components. CONCLUSIONS AND RELEVANCE: In this study of patients with HF with mildly reduced or preserved ejection fraction, dapagliflozin was associated with improvement in a broad range of individual KCCQ components, with the greatest benefits in domains related to symptom frequency and physical limitations. Potential improvements in specific symptoms and activities of daily living might be more readily recognizable and easily communicated to patients. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03619213.
引用
- Peikert, Chandra, Kosiborod, et al. Association of Dapagliflozin vs Placebo With Individual Kansas City Cardiomyopathy Questionnaire Components in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the DELIVER Trial. JAMA Cardiol. 2023. PMID: 37208998. doi:10.1001/jamacardio.2023.1342
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。